qls32015
mAbexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
2
Phase 3
1
Phase 4
0
Earliest trial started Jun 30, 2023 (NCT05920876)
Timeline
Indications
Studied for
Mechanism of action
inhibitor - GPRC5D
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07138209 | Phase 3 | Oct 31, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT07185477 | Early Phase 1 (Phase 1) | Sep 15, 2025 | China Academy of Chinese Medical Sciences |
| NCT07018050 | Phase 2 | Sep 12, 2025 | Qilu Pharmaceutical Co., Ltd. |
| NCT05920876 | Phase 1 | Jun 30, 2023 | Chinese Academy of Medical Sciences, Qilu Pharmaceutical Co., Ltd. |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Qilu Pharmaceutical Co., Ltd. | For profit | 3 | 3 | 3 | 2023 |
| China Academy of Chinese Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 0 | 1 | 2023 |
3 organizations
Page 1 / 1